PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
Three companies launch gene therapy alliance for eye diseases
Today, the companies officially announced the launch of the GEAR partnership (Evaluation of Adeno-Associated Virus Vector Gene Therapy for the...
Swiss Biotech Report reporting record turnover
The Swiss Biotech Report 2024 commissioned by the Swiss Biotech Association and co-published with EY on the occasion of the Swiss Biotech Day...
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
Roche leads Freenome Inc US$257m financing
Roche led the financing that will be used by San Francisco-based Freenome Inc to finance testing its early cancer detection platform in the Vallania...